Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Gossamer Bio Inc. (GOSS) PT Lowered to $2 at H.C. Wainwright
• Is AI momentum starting to cool? BofA weighs in